Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may Fine-Tune IVIg dosing for rare nerve disorders

NCT ID NCT04356781

Knowledge-focused Sponsor: Walton Centre NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 20 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN) who were starting intravenous immunoglobulin (IVIg) treatment. Researchers measured changes in IgG levels in the blood after the first dose to see if those changes could predict the long-term dose each patient would need. The goal is to make dosing more precise, reduce side effects, and lower costs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intravenous immunoglobulin (IVIg)
What this could lead to
If successful, this could help doctors find the right IVIg dose for each patient more quickly, saving time and reducing side effects.
What could go wrong
This is a small, completed observational study with only 20 participants. It does not test a new treatment, so it may not lead to changes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20 people

The number who actually took part.

Started

Sep 2020

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include patients with CIDP or MMN starting IVIg under the care of neurologists in The Walton Centre.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with CIDP or MMN who are starting Intravenous immunoglobulin in the Walton Centre * Informed consent Exclusion Criteria: * Previous Intravenous immunoglobulin use in the last year * Age under 18 * Lack of mental capacity to consent to treatment or to study participation * Concurrent treatment with steroids or other immunosuppressants

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic inflammatory demyelinating polyradiculoneuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy multifocal motor neuropathy Transfusion Reaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic inflammatory demyelinating polyradiculoneuropathy Multifocal motor neuropathy (MMN)

Contacts and locations

Locations

  • The Walton Centre NHS Foundation Trust

    Liverpool, Merseyside, L9 7LJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.